Published in BMC Infect Dis on July 26, 2007
A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One (2009) 2.15
Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog (2011) 1.99
Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies. Microbiology (2009) 1.60
The temporal response of the Mycobacterium tuberculosis gene regulatory network during growth arrest. Mol Syst Biol (2008) 1.56
Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis (2010) 1.39
Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo. PLoS One (2010) 1.35
The Mycobacterium tuberculosis cytochrome P450 system. Arch Biochem Biophys (2009) 1.16
Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics (2008) 1.10
Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS One (2012) 1.09
Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. Chembiochem (2008) 1.05
Target prediction for an open access set of compounds active against Mycobacterium tuberculosis. PLoS Comput Biol (2013) 1.01
Evidence for a rapid rate of molecular evolution at the hypervariable and immunogenic Mycobacterium tuberculosis PPE38 gene region. BMC Evol Biol (2009) 1.01
Determinants outside the DevR C-terminal domain are essential for cooperativity and robust activation of dormancy genes in Mycobacterium tuberculosis. PLoS One (2011) 0.98
Solution structure of the guanine nucleotide-binding STAS domain of SLC26-related SulP protein Rv1739c from Mycobacterium tuberculosis. J Biol Chem (2010) 0.97
Mycobacterium tuberculosis acg gene is required for growth and virulence in vivo. PLoS One (2011) 0.96
Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model. MBio (2015) 0.88
Global adaptation to a lipid environment triggers the dormancy-related phenotype of Mycobacterium tuberculosis. MBio (2014) 0.87
The residue threonine 82 of DevR (DosR) is essential for DevR activation and function in Mycobacterium tuberculosis despite its atypical location. J Bacteriol (2011) 0.86
Latent Tuberculosis: Models, Computational Efforts and the Pathogen's Regulatory Mechanisms during Dormancy. Front Bioeng Biotechnol (2013) 0.85
Mycobacterium tuberculosis RNA polymerase-binding protein A (RbpA) and its interactions with sigma factors. J Biol Chem (2013) 0.85
Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress response. BMC Microbiol (2011) 0.85
Wax ester synthesis is required for Mycobacterium tuberculosis to enter in vitro dormancy. PLoS One (2012) 0.85
New targets and inhibitors of mycobacterial sulfur metabolism. Infect Disord Drug Targets (2013) 0.83
Cryptococcus neoformans host adaptation: toward biological evidence of dormancy. MBio (2015) 0.82
Models of latent tuberculosis: their salient features, limitations, and development. J Lab Physicians (2011) 0.81
Increased sulfate uptake by E. coli overexpressing the SLC26-related SulP protein Rv1739c from Mycobacterium tuberculosis. Comp Biochem Physiol A Mol Integr Physiol (2007) 0.81
Novel mechanism of gene regulation: the protein Rv1222 of Mycobacterium tuberculosis inhibits transcription by anchoring the RNA polymerase onto DNA. Nucleic Acids Res (2015) 0.80
TuberQ: a Mycobacterium tuberculosis protein druggability database. Database (Oxford) (2014) 0.79
Profiling the Proteome of Mycobacterium tuberculosis during Dormancy and Reactivation. Mol Cell Proteomics (2015) 0.77
A lacZ Reporter-Based Strategy for Rapid Expression Analysis and Target Validation of Mycobacterium tuberculosis Latent Infection Genes. Curr Microbiol (2015) 0.77
New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther (2010) 0.77
Genomic and transcriptomic analysis of the streptomycin-dependent Mycobacterium tuberculosis strain 18b. BMC Genomics (2016) 0.77
Mycobacterium tuberculosis Transcription Machinery: Ready To Respond to Host Attacks. J Bacteriol (2016) 0.77
Inactivation of metabolic genes causes short- and long-range dys-regulation in Escherichia coli metabolic network. PLoS One (2013) 0.76
Activity of Medicinal Plant Extracts on Multiplication of Mycobacterium tuberculosis under Reduced Oxygen Conditions Using Intracellular and Axenic Assays. Int J Microbiol (2016) 0.76
The DosR dormancy regulator of Mycobacterium tuberculosis stimulates the Na(+)/K (+) and Ca (2+) ATPase activities in plasma membrane vesicles of mycobacteria. Curr Microbiol (2014) 0.76
Mycobacterium tuberculosis P-type ATPases: possible targets for drug or vaccine development. Biomed Res Int (2014) 0.75
Resistance related metabolic pathways for drug target identification in Mycobacterium tuberculosis. BMC Bioinformatics (2016) 0.75
The use of functional genomics in conjunction with metabolomics for Mycobacterium tuberculosis research. Dis Markers (2014) 0.75
The perilipin-like PPE15 protein in Mycobacterium tuberculosis is required for triacylglycerol accumulation under dormancy-inducing conditions. Mol Microbiol (2016) 0.75
Rapid identification and detection of intracellular survival testing of mycobacterium smegmatis mc²155 that contains eis gene from mycobacterium tuberculosis by flow cytometry. Curr Microbiol (2011) 0.75
The COG database: an updated version includes eukaryotes. BMC Bioinformatics (2003) 60.98
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
A genomic perspective on protein families. Science (1997) 50.51
The KEGG databases at GenomeNet. Nucleic Acids Res (2002) 33.68
Two-component signal transduction. Annu Rev Biochem (2000) 19.12
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
CD-Search: protein domain annotations on the fly. Nucleic Acids Res (2004) 16.76
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
Communication modules in bacterial signaling proteins. Annu Rev Genet (1992) 14.32
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 11.48
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med (2003) 10.67
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun (1996) 9.21
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol (2002) 8.90
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med (2003) 7.99
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 7.90
Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A (2001) 7.65
Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol (2001) 7.05
Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med (2005) 6.10
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol (2003) 5.68
Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA (2005) 5.39
Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A (2005) 4.43
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med (2003) 4.36
Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) (2003) 4.16
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1994) 3.92
Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) (2004) 3.70
The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A (2004) 3.63
Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis (1997) 3.55
Synchronized replication of Mycobacterium tuberculosis. Infect Immun (1977) 3.12
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol (2002) 2.94
A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med (2002) 2.87
Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci U S A (2005) 2.84
The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol (2000) 2.80
Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem (2004) 2.71
Structure-based assignment of the biochemical function of a hypothetical protein: a test case of structural genomics. Proc Natl Acad Sci U S A (1998) 2.70
A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1996) 2.70
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
The bacterial universal stress protein: function and regulation. Curr Opin Microbiol (2003) 2.54
The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol (2005) 2.52
Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol (2004) 2.51
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 2.46
Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) (2004) 2.33
Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect Immun (2006) 2.27
The effects of reactive nitrogen intermediates on gene expression in Mycobacterium tuberculosis. Cell Microbiol (2003) 2.20
Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol (2000) 2.18
Mycobacterium tuberculosis signal transduction system required for persistent infections. Proc Natl Acad Sci U S A (2001) 2.17
Carbon metabolism of intracellular bacteria. Cell Microbiol (2006) 2.17
Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob Agents Chemother (1998) 2.17
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci U S A (2005) 2.06
Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections. Antimicrob Agents Chemother (2003) 2.00
Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb) (2004) 1.92
[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris) (1982) 1.90
Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol (2000) 1.87
Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. FEMS Microbiol Lett (2004) 1.86
Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev (2006) 1.82
Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci (2004) 1.74
The Mycobacterium tuberculosis dosRS two-component system is induced by multiple stresses. Tuberculosis (Edinb) (2004) 1.74
Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiology (2001) 1.74
The sigma factors of Mycobacterium tuberculosis. FEMS Microbiol Rev (2006) 1.73
Inhibition of macrophage priming by sulfatide from Mycobacterium tuberculosis. J Immunol (1988) 1.70
Isolation and properties of a mutant of Escherichia coli with an insertional inactivation of the uspA gene, which encodes a universal stress protein. J Bacteriol (1993) 1.67
The bacteriology of resected tuberculous pulmonary lesions. I. The effect of interval between reversal of infectiousness and subsequent surgery. Am Rev Tuberc (1956) 1.63
Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis (2003) 1.58
Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun (2005) 1.58
Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J Bacteriol (2003) 1.58
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2005) 1.55
Sulfate metabolism in mycobacteria. Chembiochem (2006) 1.55
Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol (2006) 1.53
Cross talk between DevS sensor kinase homologue, Rv2027c, and DevR response regulator of Mycobacterium tuberculosis. FEBS Lett (2004) 1.53
DevR-DevS is a bona fide two-component system of Mycobacterium tuberculosis that is hypoxia-responsive in the absence of the DNA-binding domain of DevR. Microbiology (2004) 1.52
Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett (1998) 1.48
Cloning and characterization of a bifunctional RelA/SpoT homologue from Mycobacterium tuberculosis. Gene (1999) 1.47
Regulation of Mycobacterium tuberculosis cell envelope composition and virulence by intramembrane proteolysis. Nature (2005) 1.44
Role for nucleotide excision repair in virulence of Mycobacterium tuberculosis. Infect Immun (2005) 1.43
Comparative proteome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions. Microbiology (2004) 1.39
The search for new sterilizing anti-tuberculosis drugs. Front Biosci (2004) 1.39
Deletion of the Mycobacterium tuberculosis alpha-crystallin-like hspX gene causes increased bacterial growth in vivo. Infect Immun (2006) 1.38
MprAB is a stress-responsive two-component system that directly regulates expression of sigma factors SigB and SigE in Mycobacterium tuberculosis. J Bacteriol (2006) 1.34
Mycobacterium tuberculosis sigF is part of a gene cluster with similarities to the Bacillus subtilis sigF and sigB operons. Tuber Lung Dis (1997) 1.33
Properties of the 40 kDa antigen of Mycobacterium tuberculosis, a functional L-alanine dehydrogenase. Biochem J (1999) 1.31
Increased alanine dehydrogenase activity during dormancy in Mycobacterium smegmatis. FEMS Microbiol Lett (1998) 1.30
Functional genomics reveals the sole sulphate transporter of the Mycobacterium tuberculosis complex and its relevance to the acquisition of sulphur in vivo. Mol Microbiol (2002) 1.30
Reversible inhibition of the coupling between phosphorylation and oxidation. J Biol Chem (1948) 1.30
The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med (2005) 1.28
5'-adenosinephosphosulfate lies at a metabolic branch point in mycobacteria. J Biol Chem (2002) 1.27
Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med (2004) 1.27
Structures of Mycobacterium tuberculosis DosR and DosR-DNA complex involved in gene activation during adaptation to hypoxic latency. J Mol Biol (2005) 1.26
Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of genes encoding class Ib and class II ribonucleotide reductases. Infect Immun (2003) 1.23
Universal stress proteins and Mycobacterium tuberculosis. Res Microbiol (2003) 1.22
The stress-responsive chaperone alpha-crystallin 2 is required for pathogenesis of Mycobacterium tuberculosis. Mol Microbiol (2005) 1.22
Effects of overproducing the universal stress protein, UspA, in Escherichia coli K-12. J Bacteriol (1996) 1.21
The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex. Microbiology (2004) 1.15
Profiling of Mycobacterium tuberculosis gene expression during human macrophage infection: upregulation of the alternative sigma factor G, a group of transcriptional regulators, and proteins with unknown function. Res Microbiol (2006) 1.14
New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today (2006) 1.14
Tyrosine phosphorylation in Escherichia coli. J Mol Biol (1998) 1.13
Functional analysis of the Mycobacterium tuberculosis MprAB two-component signal transduction system. Infect Immun (2003) 1.13
Thousands of chemical starting points for antimalarial lead identification. Nature (2010) 8.28
Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections. Antimicrob Agents Chemother (2003) 2.00
A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J Mol Microbiol Biotechnol (2003) 1.31
Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob Agents Chemother (2003) 1.21
Comparative genomics of Klebsiella pneumoniae strains with different antibiotic resistance profiles. Antimicrob Agents Chemother (2011) 1.20
The evolution of core proteins involved in microRNA biogenesis. BMC Evol Biol (2008) 1.14
Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread. Antimicrob Agents Chemother (2005) 1.06
Target prediction for an open access set of compounds active against Mycobacterium tuberculosis. PLoS Comput Biol (2013) 1.01
Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS One (2012) 0.98
Data mining the human gut microbiota for therapeutic targets. Brief Bioinform (2012) 0.97
Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development. Toxicol Appl Pharmacol (2013) 0.94
Phylogenomic and biochemical characterization of three Legionella pneumophila polypeptide deformylases. J Bacteriol (2006) 0.87
The micro RNA target paradigm: a fundamental and polymorphic control layer of cellular expression. Expert Opin Biol Ther (2007) 0.86
Novel drug target strategies against Mycobacterium tuberculosis. Curr Opin Microbiol (2008) 0.86
Evidence from the evolutionary analysis of nucleotide sequences for a recombinant history of SARS-CoV. Infect Genet Evol (2004) 0.85
Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data. PLoS One (2013) 0.82
Molecular evolutionary analysis of cancer cell lines. Mol Cancer Ther (2010) 0.82
Modulating the human gut microbiome as an emerging therapeutic paradigm. Sci Prog (2013) 0.80
Towards the rational design of synthetic cells with prescribed population dynamics. J R Soc Interface (2012) 0.79
What is bullying? J Adolesc Health (2008) 0.79
Squeezing millimeter waves into microns. Phys Rev Lett (2004) 0.79
Bioinformatics and the discovery of novel anti-microbial targets. Curr Drug Targets Infect Disord (2002) 0.79
Computational biology in anti-tuberculosis drug discovery. Infect Disord Drug Targets (2009) 0.78
The ARO4 gene of Candida albicans encodes a tyrosine-sensitive DAHP synthase: evolution, functional conservation and phenotype of Aro3p-, Aro4p-deficient mutants. Microbiology (2002) 0.76
Connection to mental health care upon community reentry for detained youth: a qualitative study. BMC Public Health (2014) 0.75
Optimized aerial applications of two resmethrin formulations against caged Anopheles quadrimaculatus. J Am Mosq Control Assoc (2009) 0.75
Evaluation of Pioneer eco-backpack sprayer and Twister XL backpack sprayer using Aqualuer against caged adult Aedes albopictus and Culex quinquefasciatus. J Am Mosq Control Assoc (2012) 0.75
Ground ultra-low volume assessment of Aqua-Kontrol. J Am Mosq Control Assoc (2006) 0.75
Aerial ultra-low-volume assessment of ANVIL 10+10 against Anopheles quadrimaculatus. J Am Mosq Control Assoc (2005) 0.75
Preparing Nursing and Social Work Students to Care for Patients in Acute Alcohol Withdrawal. J Addict Nurs (2017) 0.75